Trailing-twelve-month (TTM) revenue is $61.37 Billion with a year-over-year growth of +8.61%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $15,191,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $15,503,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-24 |
| Q1 FY2026Period ended 2026-03-31 | $15,288,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-29 |
| Q2 FY2026Period ended 2026-06-30 | $15,384,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-27 |
| TTM revenue | $61,366,000,000 |
Current P/S: $247,581,278,397 market capitalization ÷ $61,366,000,000 TTM revenue = 4.03x.
Market capitalization source: FMP quote. Quote observed 2026-09-10T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $15.38B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-10T20:00:02.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Andexxa | N/A | N/A | N/A | $150M | $182M | N/A |
| Arimidex | $225M | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20252025-12-31 · USD |
|---|---|
| Asia, Africa And Australasia | $13.4B |
| Europe excluding the United Kingdom | $13.5B |
| The Americas | $27.6B |
| UNITED KINGDOM | $4.4B |
$61.37B
$61.37 Billion
+8.61%
vs. $56.50B a year ago (TTM)
+15.76%
5 Year compound annual growth rate
1 Year
+8.61%
3 Year
+11.32%
5 Year
+15.76%
10 Year
+9.82%
15 Year
+4.17%
20 Year
+4.62%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $58.74B | +$4.67B | +8.63% |
| 2024 | $54.07B | +$8.26B | +18.03% |
| 2023 | $45.81B | +$1.46B | +3.29% |
| 2022 | $44.35B | +$6.93B | +18.53% |
| 2021 | $37.42B | +$10.80B | +40.58% |
| 2020 |
TTM Growth
+8.61%
3-Year CAGR
+11.32%
5-Year CAGR
+15.76%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-10T20:00:02.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $99M |
| N/A |
| N/A |
| Atacand | $221M | N/A | N/A | N/A | N/A | N/A |
|---|
| Bevespi | $42M | N/A | N/A | $58M | $58M | N/A |
|---|
| BioPharmaceuticals: total Respiratory & Immunology | N/A | N/A | N/A | $5.8B | N/A | N/A |
|---|
| Breztri | $2M | N/A | N/A | $398M | $677M | $1.2B |
|---|
| Brilinta | $1.6B | N/A | N/A | $1.4B | $1.3B | $823M |
|---|
| Bydureon | $549M | N/A | N/A | $280M | $163M | N/A |
|---|
| Byetta | $110M | N/A | N/A | N/A | N/A | N/A |
|---|
| Calquence | $164M | N/A | N/A | $2.1B | $2.5B | $3.5B |
|---|
| Cardiovascular And Metabolic Diseases Products | $6.9B | N/A | N/A | N/A | N/A | N/A |
|---|
| Casodex | $200M | N/A | N/A | $78M | N/A | N/A |
|---|
| Collaboration Revenue | N/A | N/A | $12M | N/A | N/A | N/A |
|---|
| Crestor | $1.3B | $1.2B | $1.1B | $1.0B | $1.1B | $1.2B |
|---|
| CVRM | N/A | N/A | N/A | $9.2B | $10.6B | $12.8B |
|---|
| Daliresp Daxas | $215M | N/A | N/A | N/A | N/A | N/A |
|---|
| Daliresp/Daxas | N/A | N/A | N/A | $189M | $54M | N/A |
|---|
| Duaklir | $77M | N/A | N/A | N/A | N/A | N/A |
|---|
| Enhertu | N/A | N/A | $17M | $79M | $1.0B | $1.8B |
|---|
| Farxiga | $1.5B | N/A | N/A | $4.4B | $6.0B | $8.4B |
|---|
| Fasenra | $704M | N/A | N/A | $1.4B | $1.6B | $2.0B |
|---|
| Faslodex | $892M | N/A | N/A | $334M | $297M | N/A |
|---|
| FluMist | N/A | N/A | N/A | $175M | $216M | $272M |
|---|
| Imfinzi | $1.5B | N/A | N/A | $2.8B | $4.2B | $6.1B |
|---|
| Iressa | $423M | N/A | N/A | $114M | N/A | N/A |
|---|
| Kanuma | N/A | N/A | N/A | $160M | $171M | N/A |
|---|
| Koselugo | N/A | N/A | N/A | $208M | $331M | $662M |
|---|
| Lokelma | $14M | N/A | N/A | $289M | $412M | $698M |
|---|
| Losec Prilosec | $263M | N/A | N/A | N/A | N/A | N/A |
|---|
| Lynparza | $1.2B | N/A | N/A | $2.6B | $2.8B | $3.3B |
|---|
| Lynparza And Koselugo | N/A | $460M | N/A | N/A | N/A | N/A |
|---|
| Lynparza/Koselugo | N/A | N/A | $400M | N/A | N/A | N/A |
|---|
| Nexium | $1.5B | N/A | $1.3B | $1.3B | $945M | $816M |
|---|
| Oncology Products | $8.7B | N/A | N/A | N/A | N/A | N/A |
|---|
| Oncology, Others | N/A | N/A | N/A | $44M | $224M | $425M |
|---|
| Onglyza | $527M | N/A | N/A | $257M | $227M | N/A |
|---|
| Ophatys | N/A | N/A | N/A | $33M | N/A | N/A |
|---|
| Other Cardiovascular And Metabolic Diseases Products | $271M | N/A | N/A | N/A | N/A | N/A |
|---|
| Other Collaboration Revenue | N/A | $46M | N/A | N/A | N/A | N/A |
|---|
| Other Diabetes | $52M | N/A | N/A | N/A | N/A | N/A |
|---|
| Other Oncology Products | $94M | N/A | N/A | N/A | N/A | N/A |
|---|
| Other Ongoing Collaboration Revenue | N/A | N/A | $64M | N/A | N/A | N/A |
|---|
| Other Products | $2.6B | N/A | N/A | N/A | N/A | N/A |
|---|
| Other Products Others | $306M | N/A | N/A | N/A | N/A | N/A |
|---|
| Other Respiratory Products | $390M | N/A | N/A | N/A | N/A | N/A |
|---|
| Other, Others | N/A | N/A | N/A | $340M | $231M | $156M |
|---|
| Profit share revenue from product sales by collaboration partners | N/A | N/A | $200M | N/A | N/A | N/A |
|---|
| Pulmicort | $1.5B | N/A | N/A | $645M | $713M | $518M |
|---|
| Rare Disease | N/A | N/A | N/A | $7.1B | $7.8B | $9.1B |
|---|
| Respiratory Products | $5.4B | N/A | N/A | N/A | N/A | N/A |
|---|
| Respiratory, Others | N/A | N/A | N/A | $421M | N/A | N/A |
|---|
| Roxadustat | N/A | N/A | $174M | $197M | $271M | $274M |
|---|
| Royal income | N/A | N/A | $138M | N/A | N/A | N/A |
|---|
| Royal Revenue | N/A | $62M | N/A | N/A | N/A | N/A |
|---|
| Saphnelo | N/A | N/A | N/A | $116M | $280M | $686M |
|---|
| Seloken Toprol Xl | $760M | N/A | N/A | N/A | N/A | N/A |
|---|
| Seloken/Toprol-XL | N/A | N/A | N/A | $862M | $640M | N/A |
|---|
| Seroquel Xr Ir | $191M | N/A | N/A | N/A | N/A | N/A |
|---|
| Soliris | N/A | N/A | N/A | $3.8B | $3.1B | $1.8B |
|---|
| Strensiq | N/A | N/A | N/A | $958M | $1.2B | $1.7B |
|---|
| Symbicort | $2.5B | N/A | N/A | $2.5B | $2.4B | $2.9B |
|---|
| Synagis | $358M | N/A | N/A | $578M | $546M | $292M |
|---|
| Tagrisso | $3.2B | N/A | N/A | $5.4B | $5.8B | $7.3B |
|---|
| Total Oncology | N/A | N/A | N/A | $14.6B | $17.1B | $23.7B |
|---|
| Total Other medicines | N/A | N/A | N/A | $1.6B | $1.2B | $972M |
|---|
| Ultomiris | N/A | N/A | N/A | N/A | N/A | $4.7B |
|---|
| Ultomiris. | N/A | N/A | N/A | $2.0B | $3.0B | N/A |
|---|
| Vaxzevria | N/A | N/A | N/A | $1.8B | $12M | N/A |
|---|
| Zoladex | $813M | $888M | $948M | $927M | $952M | $1.1B |
|---|
| $26.62B |
| +$2.23B |
| +9.16% |
| 2019 | $24.38B | +$2.29B | +10.38% |
| 2018 | $22.09B | ($375.00M) | (1.67%) |
| 2017 | $22.46B | ($537.00M) | (2.33%) |
| 2016 | $23.00B | ($1.71B) | (6.90%) |
